Assenagon Asset Management
TBPH icon

Assenagon Asset Management’s Theravance Biopharma TBPH Stock Holding History

Assenagon Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-404,147
Closed -$6.56M – 1251
2026
Q1 		$6.56M Buy
404,147
+3
+0% +$53 0.01% 538
2025
Q4 		$7.56M Sell
404,144
-10,571
-3% -$175K 0.01% 568
2025
Q3 		$6.05M Buy
414,715
+390,735
+1,629% +$4.94M 0.01% 581
2025
Q2 		$264K Buy
+23,980
New +$233K ﹤0.01% 1097
2024
Q2 		– Sell
-40,166
Closed -$360K – 1492
2024
Q1 		$360K Buy
+40,166
New +$372K ﹤0.01% 1260

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Assenagon Asset Management's TBPH Position: Q2 2026 in Review

Assenagon Asset Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 404,147 shares — an estimated $6.56M sold.

Assenagon Asset Management first reported a position in TBPH in Q1 2024 and held it in 5 quarters. The position peaked at $7.56M in Q4 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Assenagon Asset Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 404,147 Theravance Biopharma shares in Q2 2026, an estimated $6.56M.
  • Assenagon Asset Management first reported a position in Theravance Biopharma in Q1 2024 and held it in 5 quarters.
  • Assenagon Asset Management's Theravance Biopharma position peaked at $7.56M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.